Skip to content

A study on the predictive index of efficacy of nasal high-flow oxygen therapy in patients with immunosuppression complicated with acute respiratory failure

A study on the predictive index of efficacy of nasal high-flow oxygen therapy in patients with immunosuppression complicated with acute respiratory failure

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085052
Enrollment
Unknown
Registered
2024-05-30
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression with respiratory failure

Interventions

Immunosuppression with respiratory failure group:none

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients over 18 years of age and immunosuppressed (solid or hematological malignancies, solid organ transplants, long-term or high-dose [=1mg/kg/ day] steroid therapy, other immunosuppressive therapy or solid tumor chemotherapy, HIV infection), At the same time, acute hypoxic respiratory failure is determined by the clinician to require nasal high-flow oxygen therapy (Diagnosis of hypoxic respiratory failure depends on blood gas analysis: Under the conditions of sea level, resting state and breathing air, Arterial partial pressure of oxygen (PaO2) <60mmHg. Arterial carbon dioxide partial pressure (PaCO2) < 50mmHg.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) hypercapnia (PaCO2= 50mmHg) and/or ventilation dysfunction (pH<7.25); (2) Respiratory and cardiac arrest, requiring immediate tracheal intubation; (3) Patients with weak spontaneous breathing and coma; (4) Very severe hypoxic respiratory failure (PaO2/FiO2<60mmHg); (5) Patients who changed to HFNC sequential therapy after tracheal intubation invasive ventilation treatment improved; (6) Serious non-cooperation, refusal to use HFNC treatment; (7) Patients who received HFNC treatment for less than 24 hours and their condition changed to non-invasive positive pressure ventilation or tracheal intubation mechanical ventilation; (8) Refused to participate in the study.

Design outcomes

Primary

MeasureTime frame
ROX index;mROX index;VOX index;

Secondary

MeasureTime frame
Percutaneous oxygen saturation;

Countries

China

Contacts

Public ContactYangHuan

Peking University People's Hospital

yanghuan192950@163.com+86 189 1070 9456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026